Leucine stimulates tissue protein synthesis and may also attenuate adiposity by\r\nincreasing fatty acid oxidation and mitochondrial biogenesis in muscle and adipocytes.\r\nAccordingly, the effects of a nutraceutical containing 2.25 g leucine and 30 mg pyridoxine\r\n(Vitamin B6) (NuFit active blend) were tested in cell culture and in a clinical trial. 3T3L1\r\nadipocytes were treated with leucine (0.25 mM or 0.5 mM) and/or Pyridoxal Phosphate\r\n(PLP) (50 nM or 100 nM) for 48 h. For the clinical trial, twenty overweight or obese\r\nsubjects received the NuFit active blend or placebo three times/day for 4 weeks without\r\nenergy restriction. Leucine decreased fatty acid synthase (FAS) expression and triglyceride\r\ncontent in adipocytes, and PLP addition significantly augmented this effect. Administration\r\nof NuFit active blend in the clinical trial increased fat oxidation by 33.6 g/day (p < 0.04),\r\ndecreased respiratory quotient, improved HOMAIR, reduced oxidative and inflammatory\r\nbiomarkers (plasma MDA, 8-isoprostane-F2a, TNF-a, C-reactive protein), and increased\r\nthe anti-inflammatory marker adiponectin. These data indicate that the NuFit active blend\r\nsignificantly increased fat oxidation and insulin sensitivity, and reduced oxidative and\r\ninflammatory stress. Therefore, the NuFit active blend appears to be a useful nutraceutical\r\nin the management of obesity and associated co-morbidities.
Loading....